恩替卡韦联合地塞米松治疗慢性重型乙型肝炎临床研究  

Clinical study of entecavir combined with dexamethasone for treatment of chronic severe hepatitis B

作　　者：牛龙喜[1] 郭俊岗[1] 刘旭玲[1] 刘淑珍[1] 师雁媛[1] 刘长凯[1] 

机构地区：[1]山西省大同市第四人民医院,037008

出　　处：《中国实用医刊》2011年第9期8-9,共2页Chinese Journal of Practical Medicine

摘　　要：目的探讨恩替卡韦联合地塞米松治疗慢性重型乙型肝炎的疗效。方法将128例慢性重型乙型肝炎患者随机分为治疗组64例，对照组64例，两组均给予同样的综合治疗，治疗组增加恩替卡韦和地塞米松治疗。结果治疗组血清HBV—DNA转阴率为91．5％（P〈0．01），丙氨酸氨基转移酶、血清总胆红素恢复正常率为67．2％、62．5％，总有效率为85．9％，病死率为14．1％，明显优于对照组（P〈0．05）。结论恩替卡韦联合地塞米松治疗慢性重型乙型肝炎疗效佳。Objective To investigate the effect of entecavir combined with dexamethasone treatment on chronic severe hepatitis. Methods One hundred and twenty -eight patients with chronic severe hepatitis B were randomly divided into treatment group （64 patients） and control group （64 patients）, two groups were given the same comprehensive treatment, the treatment group received entecavir and dexam- ethasone in addition. Results The serum HBV - DNA negative rate was 91.5 % （ P 〈 0.01 ） in treatment group, the ALT, TBIL normal rate were 67.2%, 62.5%, total effective rate was 85.9%, mortality was 14.1% in treatment group, which were significantly better than control group（ P 〈0.05）. Conclusions Entecavir combined with dexamethasone treatment for chronic severe hepatitis B has good effect.

关 键 词：慢性重型乙型肝炎 恩替卡韦 地塞米松 

分 类 号：R512.62[医药卫生—内科学]